混合胰岛素异构体自发地在胰腺β细胞中从酸中间体中形成
Samantha A Crawford1, Jason Groegler1, Mylinh Dang1
1Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
The Journal of biological chemistry
|September 21, 2023
概括
混合胰岛素 (HIPs) 在β细胞中通过阿斯巴酸无水化中间体自发形成. 这种新的机制产生新位,可能导致1型糖尿病和其他自身免疫性疾病.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 混合胰岛素 (HIPs) 在β细胞中形成,并与1型糖尿病的发病有关.
- HIPs含有非原生氨基酸序列,并被T细胞识别.
- 以前的HIP检测涉及胰腺小岛的质谱学.
研究的目的:
- 在人类和小鼠群岛中研究HIP形成的新机制.
- 为了阐明β细胞内HIPs的自发生成.
- 为了验证这种反应机制在体内发生的情况.
主要方法:
- 胰腺小岛的质谱分析.
- 对β细胞机制的研究.
- 检测HIP及其同位素.
主要成果:
- 在β细胞中,HIPs通过阿斯巴酸无水化物中间体自发形成.
- 确定了正规的HIP (键) 和HIP异构体 (异键).
- 质谱测量证实了岛屿中两种异构体的存在,验证了新的机制.
结论:
- 在β细胞中存在一种涉及酸的HIP形成的新奇自发机制.
- 这种反应产生了标准和异构HIP.
- 这些新位的自发形成可能在1型糖尿病和其他自身免疫性疾病中发挥作用.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
415
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
415
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin Formulations: Types and Delivery
218
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
218
Protein and Protein Structure
79.7K
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme...
A protein's shape is critical to its function. For example, an enzyme...
79.7K
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348


